Pradimicin L, a new congener of pradimicin A having the D-glucosyl-D-thomosamine moiety at the C-5 position, was isolated from Actinomaduraverrucosospora subsp. neohibisca subsp. nov. The structure of pradimicin L was deduced to be N- [[(5S;6S>5-0-[4,6-dideoxy-4-(methylamino Pradimicins A, B, C1 "4*, D, E5), FA-1 and FA-26) were previously reported to exhibit broad activity against pathogenic fungi and yeasts. They share 5,6-dihydrobenzo[a]naphthacenequinone as the common skeleton and can be distinguished from each other in the amino acid moiety (D-alanine1~4), glycine5) and D-serine6)) and in the 4'-amino group of D-thomosamine in the disaccharide moiety. Benanomicin A, which also has a 5,6-dihydrobenzo[#]naphthacenequmone skeleton, was reported to have D-alanine as the amino acid moiety and D-xylosyl-D-fucose as the C-5 disaccharide moiety7'8). In the continued search for new antifungal compounds, a new strain of Actinomadura numbered R103-3 was originally discovered which produced pradimicin L. Based on taxonomic studies described in this paper, Actinomadura verrucosospora subsp. neohibisca subsp. nov. is proposed here for strain R103-3. Comparedwith knownpradimicin analogs, pradimicin L was found to differ by a distal D-glucose in the C-5 disaccharide moiety. Like pradimicins FA-1, FA-26) and BMS-1811849), pradimicin FL was produced by directed biosynthesis in D-serine-supplemented medium so that the D-alanine moiety of pradimicin L could be replaced by D-serine. This paper deals with the taxonomy of strain R103-3, structure elucidation of pradimicins L and FL and their antifungal evaluation.
Af-nitroguanidine (5 mg/ml) and a high producer ofpradimicin L, strain A10019, was selected. Briefly each clony grown on Bn-2 agar medium [soluble starch (Nichiden Kagaku) 0.5%, glucose 0.5%, fish meat extract (Mikuni Kagaku Sangyo) 0.1%, yeast extract (Oriental Yeast) 0.1%, NZ-case (Humko Sheffield Chemical) 0.2%, NaCl 0.2%, CaCO3 0.1% and agar (Junsei Chemical) 1.6%, pH 7.0] was inoculated to production medium A consisting of soluble starch 1.0%, glucose 1.0%, L-glutamic acid 0. 1 %, L-methionine 0.05%, L-arginine 0.05%, (NH4)2SO4 0.1%, K2HPO4 0.6%, MgSO4-7H2O 0.05%, NaCl 0.05%, CaCO3 0.3% and salts solution (FeSO4-7H2O O.lg, ZnSO4-7H2O 0.1 g, MnCl2-4H2O 0.1 g in 1 liter of water) 1.0% (v/v), pH 7.0 before autoclaving (10ml/50ml-Erlenmeyer flask) and incubated at 28°C for 10 days at 200rpm on a rotary shaker. Fermentation broth was adjusted to pH 2.0 with 6n HC1and mixed with an equal volume of BuOH.The BuOHlayer was separated by centrifugation at 10,000 rpm for 10 minutes at room temperature and 10/^1 of the BuOHextract was spotted on a silica gel TLC plate (Kieselgel 60F254, 0.25mm thick, E. Merck) for identification of pradimicin L. Rf values of pradimicins with a solvent system of MeOAc-n-PrOH-28% NH4OH(3:7:4): 0.47 for A, 0.52 for B, 0.44 for C, 0.15 for L, (0.20 for FL).
Quantitation of Pradimicin Congeners
For quantitation of pradimicin congeners, the fermentation broth was centrifuged as described above. The supernatant was diluted with 0.02 n NaOH-MeOH(1 : 1), and the identity of the red color characteristic of pradimicins was measured spectrophotometrically at 500 nm. The total production of pradimicins is expressed in /ig/ml as the equivalent amount of pradimicin A (zwitterionic form, Ej0^at 500 nm= 180 at pH^ll).
Quantitative component analysis was carried out by reverse-phase HPLC. After centrifugation, the broth supernate was adjusted to pH 2.0 with 0.1 n HC1and recentrifuged. The supernate was adjusted to pH 5.0 with 0.1 n NaOHand recentrifuged. The resulting sediment was dissolved in water at pH 3.5, Fermentation of Pradimicins L and FL Strain A10019was grownand maintained on a slant ofBn-2 agar medium.Spores of the microorganism was inoculated in a 500-ml Erlenmeyer flask containing 100 ml of seed medium consisting of soluble starch 1%, glycerol 1%, yeast extract 1%, peptone (Daigo Eiyo) 0.5%, NaCl 0.3% and CaCO3 0.2%, pH 7.0 before autoclaving. The seed culture was fermented at 32°C for 7 days on a rotary shaker at 200rpm. For production of pradimicin L, a 5-ml aliquot of the seed culture was transferred to a 500-ml Erlenmeyer flask containing 100ml of production medium A. For production of pradimicin FL, 0.25% D-serine was supplemented to mediumA before autoclaving. The fermentation was carried out at 28°C for 1 1 days.
Isolation
The fermentation broth (10 liters) of strain A10019 was centrifuged and the supernate was adjusted to pH 4.1 with 6n HC1 and kept at 5°C for 2 hours. The dark red precipitates deposited were collected by filtration.
The precipitates were dissolved in 900ml of water (adjusted to pH 9.1 with 6n NaOH), and the solution was again filtered for removal of insoluble impurities. The filtrate Wasadjusted to pH2.0 and applied onto a columnof Diaion HP-20 (800ml). The resin was washed with 3 liters of water and then eluted with 2 liters of acetone-H2O (pH 2.5) (3 :2). Acetone in the eluate was evaporated in vacuo and the remaining red-colored solution was washed 3 times with 400ml each of ethyl acetate. The resulting water layer was concentrated and lyophilized to yield a dark red solid of pradimicin complex hydrochloride (4.5g The eluate (40 ml) was concentrated and lyophilized to yield 24mg of pradimicin L hydrochloride. Pradimicin FL hydrochloride (35mg) was also isolated from the fermentation broth (20 liters) of strain A10019, which was cultivated in the D-serine-supplemented mediumA.
In vitro Antifungal Activity The MICsof the antifungal agents were determined by an agar dilution method on yeast morphology agar adjusted to pH 7.0 with 1/15m phosphate buffer40. A-5-fA aliquot of fungal suspension containing 106 cells/ml, except for Trichophyton mentagrophytes No. 4329 which contained 107 cells/ml, was inoculated onto the surface of the antibiotic-containing agar plates. After incubation at 28°C for 40 hours, the lowest concentration of antibiotic causing complete inhibition of fungal growth was determined.
Vigorous Acid Hydrolysis of Pradimicins L and FL Pradimicin L (lOOmg) was dissolved in 10ml of 6n HC1 and refluxed at 115°C for 15 hours. After cooling, the precipitates were collected by filtration, washed with water and dried to afford pradimicinone I (40mg): MP >200°C (dec); FAB-MS (m-NBA), m/z 550 (M+H)+; molecular formula, C^H^NOn; UV (0.02N NaOH-MeOH, 1 : 1) imax 240nm (s 36,000), 314 (13,900), 504 (14,100). The filtrate was passed through a column of Diaion HP-20 (20 ml). Ninhydrin-positive fractions were pooled and concentrated to give a white solid (0.8mg) which was identical with an authentic sample of alanine by silica gel TLC and amino acid analysis. The stereochemistry of the alanine was determined to be the^-configuration using the chiral HPLC method (column: Excel pak SIL-C18 5B, 4.6mm i.d. x 150mm, 5/im, Yokogawa Electronic Co., mobile phase: MeOH-22mMsodium phosphate buffer (pH 7.0) containing 1% THF Pradimicin L hydrochloride (108mg) was dissolved in 36ml of 1.5n HCl-MeOHand refluxed at 80°C for 20 hours. The reaction mixture was concentrated to dryness in vacuo. The residue was dissolved in water (15 ml) and applied onto a column of Diaion HP-20 (200ml). The HP-20 column was eluted first with 300 ml of water for recovery of methyl D-glucopyranoside and then with 360 ml of acetone -H2O(pH 3.0) (60:40) for recovery of pradimicins B and L methyl esters. Fractions which were positive to anthrone -H2SO4reagent, were further purified by Sephadex LH-20 column chromatography (80 ml) using 20ml) to give a white powder (16.3mg Mild Acid Hydrolysis of Pradimicin FL Pradimicin FL hydrochloride (70mg) was dissolved in 18ml of In HC1 and refluxed at 70°C for 9.5 hours. The solution was neutralized with 6n NaOHand applied onto a column of Diaion HP-20 (25ml). The resin was washed with water (100ml) and eluted with acetone-H2O (pH 3.0) (60 : 40). The eluate (50ml) was concentrated and lyophilized to give a crude deglucosylpradimicin FL solid (40mg). The solidwas dissolvedin 10ml ofCH3CN-0.15% KH2PO4(pH 3.5) (25 : 75) and subjected to reverse-phase silica gel (RP-18, 2.2 liters) column chromatography using the same solvent system. Fractions containing deglucosylpradimicin FL were combined (5. 1 liters) and concentrated in vacuo. The concentrate was applied onto a column of Diaion HP-20 (60 ml). The column was washed with water and eluted with acetone -H2O (pH 3.0) (4 : 1). The eluate (50ml) was evaporated to yield pure deglucosylpradimicin FL hydrochloride 
General
Spectral data were recorded with the following instruments: IR, JASCOIR-8 10 spectrometer; UV-vis, JASCO UVIDEC-610 spectrometer; XH and 13C NMR, JEOL JMN-GX 400 spectrometer; FAB-MS and HRFAB-MS,JEOL JMS-AX505H spectrometer.
Results and Discussion
Taxonomy Strain R103-3 formed well-branched, non-fragmenting substrate mycelia and short aereal mycelia on agar media. Loop or spiral short spore chains (5~12 spores per chain) were formed on the aerial hyphae. (15) Very dark red (17) Grayish pink (8) (14) Light yellowish pink (28) Light pink (4) Dark red (16) Blackish red (21) Observation after incubation at 28°C for 3 weeks. Color name used: ISCC-NBSColor-Name Charts. Basal medium: Pridham-Gottlieb medium (ISP 9), CuSO4 -7H2O omitted. MAR. 1993 sporangium-like vesicles and sclerotia were not observed. Well sporulating aerial mycelia were formed on ISP media Nos. 3, 4, 5 and 7. Reddish diffusible pigments including pradimicins were produced in Czapeck's agar and organic media such as ISP mediumNo. 2. Cultural and physiological characteristics are shown in Tables 1 and 2 , respectively.
The whole cell hydrolyzate contained raeso-diaminopimelic acid, glucose and madurose. The phospholipids consisted of phosphatidylglycerol and phosphatidylinositol without nitrogenous phospholipids. Therefore, strain R103-3 belonged to the wall type III, sugar pattern B and phospholipid type P-I. The major menaquinones consisted of MK-9 (H6), MK-9 (H4) and MK-9 (H8) (53%, 24% and 13%, respectively) together with minor components such as MK-9 (H2) and MK-9 (H10). The major cellular fatty acid compositions contained n-16:0, 18: 1, lOMe 18:0 and rc-18:0 (39%, 27%, 15% and 6%, respectively). different from Actinomadura hibisca, a pradimicin producer ( Table 3 ). As shown in Table 4 , strain R103-3 seemed to be more closely related to A. verrucosospora than the others, although the former was differentiated from A. verrucosospora in Table 4 . Differential characteristics of Actinomadura madurae ATCC19425T, Actinomadura verrucosospora ATCC27299T and Actinomadura cremea INA 292T from R103-3. terms of the production of nitrate reductase, the absence of acid production from adonitol, glycerol and trehalose and the lack of decomposition of hypoxanthine. In addition, no strain of A. verrucosospora was reported to produce a diffusible red pigment generated by benzo[a]naphthacenequinone or related chromophores. Thus, strain R103-3 was identified as a new subspecies ofA. verrucosospora and is proposed to name Actinomadura verrucosospora subsp. neohibisca subsp. nov. Tomita (Origin: neo'hi-biska, L, n.; Gr hibiskos rose mallow, a plant with reddish flower referring to a new red pigmented organism). Type strain, strain R103-3, is a single isolate and has been deposited with the American Type Culture Collection under the accession number ATCC53930.
Fermentation and Purification Total production and the component ratio of pradimicins including L and FL by strain A10019 in the presence and absence of D-serine are shown in Table 5 . Pradimicin FL was not produced in 0.25% L-serine-supplemented medium A (data not shown). Pradimicin L (or FL) was purified by HP-20 adsorption and reverse-phase silica gel column chromatography.
Physico-chemical Properties and Structural Elucidation
The physico-chemical properties of pradimicins L and FL hydrochlorides are shown in Table 6 . The UVand visible spectra of these antibiotics under acidic and alkaline conditions, along with the IR spectra werequite similar to those of pradimicin1>2), indicating that they share a common chromophoreof Quantitative componentanalysis was carried out by reverse-phase HPLCas described in Materials and Methods. ppm (multiplicity). Pradimicin FL is closely similar to pradimicin L in the UVand IR spectra ( Table 6 ). The molecular formula of pradimicin FL was estimated to be C41H46N2O20 by FAB-MS spectrometry. Pradimicin FL differs by 16 mass units from pradimicin L. In the XHNMRspectrum of pradimicin FL (Table   7) , the 17-CH3 signal at S1.34
in pradimicin L or 5 1.35 in pradimicin A is missing, while new signals around <5 3.70^-3.80 (m) assignable to 17'-CH2OHare observed. Proton signals at C-6" in pradimicin FL are exactly identical with those of pradimicin L, which indicates that pradimicin FL also possesses the D-glucose moiety like pradimicin L. Mild acid hydrolysis (I n HC1, 70°C, 9.5 hours) of pradimicin FL yielded deglucosylpradimicin FL, whose structure was established by comparing with an authentic sample prepared from pradimicin FA-1 (Tables 7 and 8 ). Vigorous acid hydrolysis of pradimicin FL yielded pradimicinone Is along with a small a Yeast morphologyagar adjusted to pH7.0 with 1/15mphosphate buffer. Determinedafter incubation for 40 hours at 28°C {Trichophyton mentagrophytes: 60 hours, 28°C). b Inoculum size 106 cells/ml {Trichophyton mentagrophytes'. 107 cells/ml).
quantity of D-serine, which was confirmed to have the^-configuration as the amino acid side chain. Consequently, pradimicin FL was concluded to have D-serine in place of D-alanine of pradimicin L. The structures of pradimicins L and FL and their degradation products, pradimicinones I and Is, were determined as illustrated in Fig. 3 .
In Vitro Antifungal Activity MICs for pradimicins L, FL and A against fungi and yeasts are shown in Table 9 . Pradimicins L and FL show a broad-spectrum of antifungal activity with MICs ranging from 1.6 to 6.3 /zg/ml. Pradimicin FL appears to be more active than pradimicins L and A against Saccharomyces cerevisiae, Candida albicans, Candida tropicalis, Cryptococcus neoformans, Aspergillus fumigatus and Trichophyton mentagrophytes. The antifungal activities of pradimicins L and FL indicate a probability that the distal sugar in pradimicin A can be replaced with other sugars without significant loss of anitifungal activity. In view of urgency in the development of fungicidal and less toxic antifungal agents for life-threatening fungal infections, screening of microbial products in the pradimicin family should be continued.
